Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 601–700 of 1,000
Kontoyiannis, D. P., Bassetti, M., Nucci, M., Capparella, M. R., Yan, J. L., Aram, J. A., & Hogan, P. A. (2017) · Mycoses · doi:10.1111/myc.12641 · Cited by 22
Aqueous Humor Concentrations of Topically Administered Caspofungin in Rabbits
Vorwerk, C. K., Tuchen, S., Streit, F., Binder, L., Hofmüller, W., & Behrens‐Baumann, W. (2008) · Ophthalmic Research · doi:10.1159/000187627 · Cited by 22
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03712.x · Cited by 22
Present situation in the treatment of invasive fungal infection
Pauw, B. E. D., & Picazo, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70020-7 · Cited by 25
Candidaemia in the non-neutropenic patient: A critique of the guidelines
Deshpande, A., Gaur, S., & Bal, A. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.005 · Cited by 26
Treatment of invasive candidiasis with echinocandins
Glöckner, A., Steinbach, A., Vehreschild, J. J., & Cornely, O. A. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01645.x · Cited by 23
Increasing Fungal Infections in the Intensive Care Unit
Pauw, B. E. D. (2006) · Surgical Infections · doi:10.1089/sur.2006.7.s-93 · Cited by 24
Arikan, S., Sancak, B., & Hascelik, G. (2005) · Medical Mycology · doi:10.1080/13693780410001731565 · Cited by 21
Zaragoza, R., & Pemán, J. (2006) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(06)70014-6 · Cited by 25
Anidulafungin for the treatment of invasive candidiasis
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03448.x · Cited by 25
Fungal infections after hematopoietic stem cell transplantation
Asano‐Mori, Y. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0574-0 · Cited by 22
Echinocandins--new antifungal agents.
Stan, C. D., Tuchiluş, C., & Stan, C. I. (2014) · The Medical-Surgical Journal · Cited by 26
Current Role of Echinocandins in the Management of Invasive Aspergillosis
Mikulska, M., & Viscoli, C. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0216-6 · Cited by 25
Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective
Kleinberg, M. E. (2005) · Medical Mycology · doi:10.1080/13693780400025237 · Cited by 21
Pharmacokinetics of antifungal agents in children
Watt, K., Benjamin, D. K., & Cohen‐Wolkowiez, M. (2011) · Early Human Development · doi:10.1016/j.earlhumdev.2011.01.014 · Cited by 25
Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran
Gharaghani, M., Halvaeezadeh, M., Jalaee, G. A., Taghipour, S., Kiasat, N., & Mahmoudabadi, A. Z. (2020) · Current Medical Mycology · doi:10.18502/cmm.6.2.2696 · Cited by 21
Antifungal resistance: the clinical front.
Perfect, J. R. (2004) · PubMed · Cited by 28
Self-citationNew options for treatment of candidaemia in critically ill patients
Ruhnke, M., Härtwig, K., & Kofla, G. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01981.x · Cited by 25
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)
Jarque, I., Tormo, M., Bello, J. L., Rovira, M., Batlle, M., Juliá, A., Tabares, S., Rivas, C., Fernández-Sevilla, A., García‐Boyero, R., et al. (2013) · Medical Mycology · doi:10.3109/13693786.2012.693213 · Cited by 21
Wiederhold, N. P., Najvar, L. K., Matsumoto, S., Bocanegra, R. A., Herrera, M., Wickes, B. L., Kirkpatrick, W. R., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04857-14 · Cited by 21
Nakagawa, Y., Umegawa, Y., Nonomura, K., Matsushita, N., Takano, T., Tsuchikawa, H., Hanashima, S., Oishi, T., Matsumori, N., & Murata, M. (2014) · Biochemistry · doi:10.1021/bi5012942 · Cited by 23
Micafungin: the US perspective
Zaas, A. K., & Steinbach, W. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.2.183 · Cited by 22
Ellis, M. E., Frampton, C., Joseph, J., Alizadeh, H., Kristensen, J., Hauggaard, A., & Shammas, F. V. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46452-0 · Cited by 21
Elalouf, A., Elalouf, H., & Rosenfeld, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292625 · Cited by 24
Wu, X., Wu, J., Wang, P., Fang, X., Yu, Y., Tang, J., Xiao, Y., Wang, M., Li, S., Zhang, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1513 · Cited by 25
Rubio-Rodríguez, D., Grau, S., Pozo, J. C., Romá, E., Salavert, M., Barrueta, J. A., Peral, C., Rodriguez, I., & Rubio‐Terres, C. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s91587 · Cited by 28
Najvar, L. K., Bocanegra, R. A., Wiederhold, N. P., Lambros, C., Najarian, N., Patterson, T. F., & Graybill, J. R. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01994.x · Cited by 20
Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients
Fisher, B. T., & Zaoutis, T. E. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00003 · Cited by 22
Very Low Prevalence of Endophthalmitis in Very Low Birthweight Infants who Survive Candidemia
Fisher, R. G., Karlowicz, M. G., & Lall-Trail, J. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211300 · Cited by 21
Fungal infections of the bones and joints
Johnson, M. D., & Perfect, J. R. (2007) · Current Infectious Disease Reports · doi:10.1007/s11908-007-1002-3 · Cited by 20
Self-citationThe Diagnostic and Therapeutic Approach to Fungal Infections in Critical Care Settings
Zaragoza, R., & Pemán, J. (2008) · Cited by 21
Hepatotoxicity of Antimicrobials and Antifungal Agents
Moseley, R. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00026-1 · Cited by 28
Lin, K., Chen, P., Chuang, Y., Wang, J., Sun, H., Sheng, W., Chen, Y., & Chang, S. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.05.011 · Cited by 24
Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
Allen, U. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/784549 · Cited by 21
Caspofungin in the treatment of candidosis and aspergillosis
Maertens, J. A., & Boogaerts, M. (2003) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(03)90003-8 · Cited by 23
Wu, J., Xie, S., Zhang, G., Zhan, J., Xie, W., Yu, R., Xue, B., Cen, Y., Chai, J., Chen, H., et al. (2014) · Burns & Trauma · doi:10.4103/2321-3868.130182 · Cited by 24
Antifungal agents for the treatment of systemic fungal infections in children
Allen, U., Canadian Paediatric Society, & Infectious Diseases and Immunization Committee (2010) · Paediatrics & Child Health · doi:10.1093/pch/15.9.603 · Cited by 32
Relationship between the initial dose of micafungin and its efficacy in patients with candidemia
Ota, Y., Tatsuno, K., Okugawa, S., Yanagimoto, S., Kitazawa, T., Fukushima, A., Tsukada, K., & Koike, K. (2007) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0522-y · Cited by 20
NOVIDADES EM FÁRMACOS ANTIFÚNGICOS: UMA REVISÃO
Bergold, A. M., & Georgiadis, S. (2004) · Visão Acadêmica · doi:10.5380/acd.v5i2.562 · Cited by 20
Efficacy of caspofungin in invasive candidiasis and candidemia – de‐escalation strategy
Lichtenstern, C., Nguyen, T. H., Schemmer, P., Hoppe‐Tichy, T., & Weigand, M. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01527.x · Cited by 20
Infecciones asociadas a dispositivos intravasculares utilizados para la terapia de infusión
Fortün, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13116754 · Cited by 31
Ito‐Takeichi, S., Niwa, T., Fujibayashi, A., Suzuki, K., Ohta, H., Niwa, A., Tsuchiya, M., Yamamoto, M., Hatakeyama, D., Suzuki, A., et al. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12809 · Cited by 22
Das, T., Joseph, J., Jakati, S., Sharma, S., Velpandian, T., Padhy, S. K., Das, V. A., Shivaji, S., Nayak, S., Behera, U. C., et al. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2329_21 · Cited by 20
Smolobochkin, А. V., Gazizov, A. S., Appazov, N. O., Sinyashin, O. G., & Burilov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011158 · Cited by 20
Glöckner, A., & Cornely, O. A. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02208.x · Cited by 21
Current treatment of severe sepsis
Cinel, İ., & Dellinger, R. P. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0046-0 · Cited by 19
Arend, S. M., Kuijper, E. J., Vaal, B. J., de Fijter, J. W., & Wout, J. W. V. ’. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0066-y · Cited by 19
Significant Publications on Infectious Diseases Pharmacotherapy in 2016
Fong, G. R., Skoglund, E. W., Phe, K., Guastadisegni, J. M., Shea, K. M., McDaneld, P. M., Perez, K. K., & Sofjan, A. K. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017727212 · Cited by 21
From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature
Wiederhold, N. P., & Gibas, C. F. C. (2018) · Journal of Fungi · doi:10.3390/jof4040138 · Cited by 20
Echinocandins: a wealth of choice – how clinically different are they?
Zaas, A. K. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328307c79c · Cited by 24
Andes, D. R. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.002 · Cited by 20
Caspofungin: A Potential Cause of Reversible Severe Thrombocytopenia
Lynch, J. A., & Wong‐Beringer, A. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.14.1408.43148 · Cited by 19
Secular trends in mortality associated with new therapeutic strategies in surgical critical illness
Hartl, W. H., Wolf, H., Schneider, C. P., Küchenhoff, H., & Jauch, K. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.12.043 · Cited by 19
Caspofungin in a pediatric patient with persistent candidemia
Wertz, K. K., & Pretzlaff, R. K. (2004) · Pediatric Critical Care Medicine · doi:10.1097/01.pcc.0000113264.00053.af · Cited by 19
Michl, T. D., Giles, C., Mocny, P., Futrega, K., Doran, M. R., Klok, H., Griesser, H. J., & Coad, B. R. (2017) · Biointerphases · doi:10.1116/1.4986054 · Cited by 19
Molecular Mechanisms of Antifungal Resistance in Mucormycosis
Ganesan, P., Ganapathy, D. M., Sekaran, S., Murthykumar, K., Sundramoorthy, A. K., Sivaperumal, P., & Rajeshkumar, S. (2022) · BioMed Research International · doi:10.1155/2022/6722245 · Cited by 18
Miyazaki, T., & Kohno, S. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1058157 · Cited by 20
Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis
Maertens, J. A. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.019 · Cited by 19
Nephrotoxicity in the setting of invasive fungal diseases
Ullmann, A. J. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01525.x · Cited by 18
Comparison of BACTEC™ blood culture media for the detection of fungemia
Datcu, R., Boel, J. B., Jensen, I., & Arpi, M. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2781-y · Cited by 18
Formas lipídicas de anfotericina
Botero, M. C., Puentes-Herrera, M., & Cortés, J. A. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000500002 · Cited by 25
Caspofungin for Invasive Candidiasis at a Tertiary Care Medical Center
Zaas, A. K., Ashley, E. S. D., Alexander, B. D., Johnson, M. D., & Perfect, J. R. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.029 · Cited by 19
Self-citationInvasive fungal infection--laboratory diagnosis and antifungal treatment.
Shao, P. L., Huang, L., & Hsueh, P. (2006) · PubMed · Cited by 19
Wegner, B., Baer, P. C., Gauer, S., Oremek, G. M., Hauser, I. A., & Geiger, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh948 · Cited by 18
Infections in the Cancer Patient
Marchetti, O., Tissot, F., & Calandra, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00079-4 · Cited by 22
Dignani, M. C., Solomkin, J. S., & Anaissie, E. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00008-6 · Cited by 34
Safdar, A., & RAAD, I. I. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-8010-7_7 · Cited by 18
Evolving strategies in the management of aspergillosis
Magill, S. S., Chiller, T. M., & Warnock, D. W. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.193 · Cited by 19
Hope, W. W., Warn, P. A., Sharp, J., Reed, P., Keevil, B. G., Louie, A., Denning, D. W., & Drusano, G. L. (2005) · The Journal of Infectious Diseases · doi:10.1086/432069 · Cited by 20
Clinical consequences of resistant Candida infections in intensive care
Montravers, P., & Jabbour, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.11.002 · Cited by 19
Zaragoza, R., Ferrer, R., Maseda, E., Llinares, P., & Rodríguez, A. H. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2014.06.001 · Cited by 17
Sakai, D., Matsumiya, W., Kusuhara, S., & Nakamura, M. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-021-00248-0 · Cited by 21
Cornely, O. A., Vázquez, J. A., Waele, J. J. D., Betts, R. F., Rotstein, C., Nucci, M., Pappas, P. G., & Ullmann, A. J. (2013) · Mycoses · doi:10.1111/myc.12104 · Cited by 21
Self-citationBailly, S., Leroy, O., Azoulay, É., Montravers, P., Constantin, J., Dupont, H., Guillemot, D., Lortholary, O., Mira, J. P., Pérrigault, P.-F., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.12.016 · Cited by 17
Ortega, R. D. D. L., D'Arcy, D. M., Lamprou, D. A., & Fotaki, N. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.03.001 · Cited by 17
Tashiro, S., Osa, S., Igarashi, Y., Watabe, Y., Liu, X., Enoki, Y., Taguchi, K., Mayumi, T., Miyazaki, Y., Takesue, Y., et al. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.06.008 · Cited by 19
Kato, H., Hagihara, M., Shibata, Y., Asai, N., Yamagishi, Y., Iwamoto, T., & Mikamo, H. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.06.017 · Cited by 19
Fisher, B. T., Zaoutis, T. E., Xiao, R., Wattier, R. L., Castagnola, E., Pana, Z. D., Fullenkamp, A., Boge, C. L. K., Ross, R. K., Yildirim, I. B., et al. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab024 · Cited by 18
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 20
Pfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 21
Peritonitis and Intraperitoneal Abscesses
Levison, M. E., & Bush, L. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00076-x · Cited by 21
Gubler, C., Wildi, S., Imhof, A., Schneemann, M., & Müllhaupt, B. (2007) · Infection · doi:10.1007/s15010-007-6165-1 · Cited by 18
Refractory pulmonary aspergillosis treated with caspofungin after heart-lung transplantation
Carby, M. R., Hodson, M. E., & Banner, N. R. (2004) · Transplant International · doi:10.1007/s00147-004-0753-0 · Cited by 17
Caspofungin: a new therapeutic option for fungal endocarditis
Nevado, J., de Alarcón, A., & Hernández, A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01078.x · Cited by 17
Overview of transplant mycology
Golan, Y. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.suppl_1.s17 · Cited by 17
Antifungal Clinical Trials and Guidelines: What We Know and Do Not Know
Pappas, P. G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019745 · Cited by 18
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
Reinhold, I., Picardi, S., Liss, B., Seidel, D., Stemler, J., Koehler, P. A., Ruegamer, T., Sprute, R., & Cornely, O. A. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00409-8 · Cited by 25
Wiederhold, N. P., & Patterson, T. F. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000203 · Cited by 23
Multi‐state evaluation of Candida infections in burn patients
Salimi, M., Javidnia, J., Abastabar, M., Mobayen, M., Moslemi, A., Rahimzadeh, G., Charati, J. Y., Tirabadi, N. M., Nouranibaladezaei, S., Asghari, H., et al. (2024) · Mycoses · doi:10.1111/myc.13788 · Cited by 17
Bernhardt, H., Knoke, M., & Bernhardt, J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02036.x · Cited by 18
Roohani, A. H., Fatima, N., Shameem, M., Khan, H. M., Khan, P. A., & Akhtar, A. (2018) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_18_258 · Cited by 20
Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern?
Sanguinetti, M., Posteraro, P., & Posteraro, B. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0131-2 · Cited by 17
Metergoline-induced cell death in Candida krusei
Kang, K., Wong, K., Fong, W., & Tsang, P. W. (2011) · Fungal Biology · doi:10.1016/j.funbio.2011.01.001 · Cited by 19
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Riedel, A., Choe, L., Inciardi, J. F., Yuen, C., Martin, T., & Guglielmo, B. J. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-70 · Cited by 20
Epidemiology and antifungal susceptibility of Candida species isolated from hospitalized patients
Kalkancı, A., Berk, E., Aykan, B., Çağlar, K., Hızel, K., Arman, D., & Kuştımur, S. (2007) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2006.11.003 · Cited by 16
Efficacy and safety of caspofungin in obese patients
Ryan, D., Lupinacci, R. J., & Kartsonis, N. A. (2011) · Medical Mycology · doi:10.3109/13693786.2011.571293 · Cited by 16
Self-citationTratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas
Mensa, J., de la Cámara, R., Carreras, E., Estrella, M. C., Rodríguez, J. Á. G., Gobernado, M., Picazo, J., Aguado, J. M., & Sanz, M. Á. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.01.008 · Cited by 19
Drugs Active against Fungi, Pneumocystis, and Microsporidia
Rex, J. H., & Stevens, D. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00039-4 · Cited by 18
Invasive fungal infections in cancer patients
Anaissie, E. J., Grazziutti, M., & Nucci, M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00020-7 · Cited by 19
Defining standards of CARE for invasive fungal diseases in the ICU
Cuenca‐Estrella, M., Kett, D. H., & Wauters, J. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz038 · Cited by 18
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.